Navigation Links
Genetic Immunity to Present at 2008 BIO International Convention
Date:6/12/2008

rove the immunigenicity of antigens and induce effective immune responses. NanoComp has also demonstrated proof of concept with the DermaVir Patch, which includes HIV-specific plasmid DNA encoded antigens.

About Genetic Immunity(R)

Genetic Immunity is a US/Hungarian clinical stage biopharmaceutical company establishing leadership in Nanomedicines for targeted immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. The Company aims to discover, develop and commercialize topically administered nanomedicines that can create new markets for treating infectious diseases, cancer and allergies. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. The DermaVir Patch, Genetic Immunity's lead nanomedicine candidate, is in Phase II clinical development and could be the first nanomedicine immune therapy for HIV-infected individuals. The DermaVir Patch has demonstrated excellent safety, immunogenicity and antiviral efficacy in preclinical studies. Phase I/II trials to date have confirmed safety and tolerability and indicate the induction of long-lasting HIV-specific memory T cells.

About the Nanomedicine Technology Platform

Genetic Immunity's nanomedicine immune amplification platform technology is comprised of two principal components: NanoComp and DermaPrep. NanoComp is a patented nanoformulation technology that includes disease-specific plasmid DNA encoded antigens. DermaPrep is the topical administration device that delivers NanoComp into a patient's lymph node dendritic cells to induce T cell mediated immune responses that can treat a broad spectrum of diseases. These two components together make up the DermaVir Patch. The plasmid DNA within DermaVir Patch's NanoComp nanoparticles is specific to HIV and topically delivered via DermaPrep to amplify the imm
'/>"/>

SOURCE Genetic Immunity
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
2. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
3. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
4. Presentation of Data on Progens Cancer Epigenetic Targets Platform
5. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
6. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
7. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
10. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
11. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)... A study published in the,scientific journal Natur...rted that InVitria,s ( http://www.InVitria.com ) C...effective replacement to bovine serum albumin,in E...d state of embryonic stem cell,self-renewal," disc...nant,albumin in place of animal-derived serum to e...
(Date:10/7/2008)...ligen Therapeutics Inc.,today announced that in vi...dates were presented at the XXII International Com...ighlighted the candidates, efficacy in,several ani...se highlighted presentations, as well as several i...l the deep expertise and expanding,knowledge base ...
(Date:10/7/2008)...g-term benefits and value in,moderate to severe Cr...ge,of Gastroenterology (ACG), ORLANDO, Fla. Oct. ...presented this week by UCB at the American College...ate that CIMZIA(R) (certolizumab pegol) - the,only...lpha) - provides,sustained improvement in symptoms...
(Date:10/7/2008)... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) announce...and Highly Selective MEK1/2 Inhibitor is Beneficia...ic Colitis in Mice," was presented at the,American...ting in Orlando,Florida. The poster, which provid...ompany,s lead mitogen-activated ERK kinase (MEK) i...
Breaking Medicine Technology:In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4Philadelphia Insurance Companies Launches Home Health Care and Hospice Products 20892 1Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 1Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 2Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 3Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 4Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 5Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 6Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 7Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 8Breast Feeding More Protective for Girls Than Boys 20888 1Breast Feeding More Protective for Girls Than Boys 20888 2Boca Pharmacal Receives FDA Approval for Carbinoxamine Maleate 4 mg Tablet 20882 1
(Date:10/7/2008)... Licensed Chiropractor Dr. Richard A. ... Newburgh, NY (Vocus) October 7, 20...one of the most stressful times in its history. H...ng costs of everything from phone bills to electri...creased stress. And with growing stress levels co...
(Date:10/7/2008)... Mickie Bellah,s Luminescence Series p...International Fine Art Gallery in the Chelsea Dist...Austin, TX (PRWEB) October 7, 2008 -- Austin Artis...ning of her Luminescence Series paintings at Amste... Chelsea District of New York City,October 10, 200...
(Date:10/6/2008)...s sold not helping fight against childhood obesity...(HealthDay News) -- Three-quarters of middle schoo...drinks are sold, a new study finds. , The resea...n most middle schools, and "that those vending mac...aid study author Amy Virus, a registered dietitian...
(Date:10/6/2008)..., Oct. 6 /PRNewswire-FirstCall/ -- Volcano Corpora..., manufacturing and sales of,products for the diag...ery,disease, today announced the relocation of its... Rancho Cordova to San Diego. The new corporate,he... San Diego and now,houses corporate executives, ma...
Breaking Medicine News(10 mins):Health News:Prescriptions for Stress 2Health News:Prescriptions for Stress 3Health News:Vending Machines Found in Most Middle Schools 2Health News:Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego 2Health News:Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego 3Health News:Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego 4
... Respiratory and Critical Care Medicine says that ... in the blood could// help detect abnormal lesions...arker of inflammation and measuring the blood leve...ople at risk for developing lesions that could cau...
...nd after the health authorities promised to pay at...ding their safety and working hours//. As word sp... of patients poured into the hospitals. Long queue...ospitals. 'It could not have come at a better tim...
...ions of the oral cavity can be effectively treated...archers from the University at Buffalo's School of...y employed in cancer treatment. PDT is currently e...arcoma, breast cancer (spread to the chest wall) a...
...rd flu, it has been proposed to construct military...ovide the best help in the avian influenza fight. ...ished in the internationally acclaimed Nature jour...hrough co-ordination between such international la...
Other Medicine News:Health News:Infections Of The Oral Cavity Can Be Treated By Photodynamic Therapy 2
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish.
Narrow 4 mm long smooth platform. Serrated handle with polished finish.
1 mm smooth 45 degrees angled jaws. Cross action serrated handle with polished finish.
Oval solid 16 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 14 mm. Serrated handle with locking thumb screw and polished finish.
Medicine Products: